Brain Tumor Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Tumor Type (Malignant Brain Tumors, Benign Brain Tumors, Glioblastoma Multiforme (GBM), Astrocytomas, Meningiomas, Pituitary Tumors, Others), By Drug Class (Alkylating Agents, Antimetabolites, Angiogenesis Inhibitors, EGFR Inhibitors, Immune Checkpoint Inhibitors, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research & Academic Institutes, Others) and Region Forecast 2020-2031

Brain Tumor Therapeutics Market size was valued at US$ 3,350.1 million in 2024 and is expected to reach US$ 5,558.0 million by 2031, growing at a significant CAGR of 7.2% from 2025-2031. Moreover, the U.S Brain Tumor Therapeutics Market is projected to grow at 7.4% of CAGR over the forecast period. The market refers to the global industry focused on the development, production, and commercialization of drugs, therapies, and treatment modalities aimed at managing and treating brain tumors. This market encompasses a wide range of therapeutic approaches, including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical adjunct treatments. It primarily addresses both malignant and benign brain tumors, with the goal of improving patient survival rates, reducing tumor progression, and enhancing quality of life.

The market is witnessing steady growth driven by rising incidence of brain cancers, advancements in diagnostic imaging, and increasing adoption of personalized medicine. A surge in research and development activities, supported by regulatory approvals of novel drugs and targeted therapies, has further accelerated market expansion. Additionally, growing awareness about neurological disorders, improved healthcare infrastructure, and government as well as non-government funding for cancer research are contributing significantly to market growth. However, challenges such as high treatment costs, limited availability of advanced therapies in developing regions, and the complexity of brain tumor biology continue to restrain widespread adoption.

Facts & Figures

• In fact, the overall five-year survival rate for primary brain tumors is about 75.7%, while malignant brain tumors have only 23.5% survival.
• Each year, around 300,000 people worldwide are affected by glioblastoma.
• In the U.S., glioblastoma affects about 5 people per 100,000 annually, with a median survival of 14–14.5 months and only 5% surviving five years.
• There are over 3,000 registered interventional clinical trials for malignant CNS tumors, nearly 47% focused on glioblastoma.
• Glioblastoma accounts for about 47.7% of all gliomas and 26% of all brain tumors, with a five-year survival rate of just 6.8%.
• Meningiomas represent about 37% of all brain tumors, with an incidence of 9.5 per 100,000 people and a five-year survival rate of 91%.

Key Developments:

• In August 2025, Jazz Pharmaceuticals, plc., announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Modeyso™ (dordaviprone). The therapy is indicated for adult and paediatric patients aged one year and older with diffuse midline glioma harboring an H3 K27M mutation, who have experienced disease progression following prior treatment. The company noted that continued approval for this indication may depend on confirmation and further description of clinical benefit in the ongoing Phase-3 ACTION confirmatory trial.
• In June 2025, Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced that the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application (No. 168178) for REYOBIQ™ (Rhenium Re186 Obisbemeda). The therapy is intended for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The upcoming study will be conducted under the name ReSPECT-PBC trial and is supported by a $3.0 million research grant awarded by the U.S. Department of Defense.

Brain Tumor Therapeutics Market Segmentation:

Based on the tumor type:

• Malignant Brain Tumors
• Benign Brain Tumors
• Glioblastoma Multiforme (GBM)
• Astrocytomas
• Meningiomas
• Pituitary Tumors
• Others

Among tumor types, Glioblastoma Multiforme (GBM) is anticipated to lead the market due to its aggressive nature and high prevalence among malignant brain tumors. GBM accounts for most primary brain cancer cases and is associated with poor prognosis, creating an urgent demand for effective therapies. This rising incidence drives extensive research investments, leading to advancements in targeted therapies, immunotherapies, and combination treatment approaches. Moreover, frequent regulatory approvals and ongoing clinical trials focusing on GBM further accelerate market growth. The pressing medical need and continuous innovation position GBM as the dominant segment in this market.

Based on the drug class:

• Alkylating Agents
• Antimetabolites
• Angiogenesis Inhibitors
• EGFR Inhibitors
• Immune Checkpoint Inhibitors
• Others

Among drug classes, Alkylating Agents are anticipated to hold the leading share in the market due to their widespread use as a standard first-line treatment for various brain tumors, particularly glioblastomas. These agents, such as temozolomide, are highly effective in damaging the DNA of cancer cells, thereby preventing tumor growth and proliferation. Their established role in treatment protocols, strong clinical efficacy, and broad availability make them the preferred choice in both developed and developing regions. Additionally, their integration with radiation therapy has further enhanced treatment outcomes, reinforcing the dominance of alkylating agents within the market.

Based on the end user:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research & Academic Institutes
• Others

Among end users, Hospitals are expected to dominate the market owing to their advanced infrastructure, availability of multidisciplinary treatment approaches, and access to specialized neurosurgical and oncology teams. Hospitals serve as the primary centers for diagnosis, surgery, radiation therapy, and administration of chemotherapy or targeted drugs, making them the most relied-upon facilities for comprehensive brain tumor management. The presence of cutting-edge imaging technologies, intensive care units, and clinical trial facilities further strengthens their role. Additionally, hospitals benefit from strong reimbursement frameworks and government support, which enhances patient accessibility, solidifying their position as the leading end-user segment.